ClearPoint Neuro (CLPT) EBIT Margin (2011 - 2026)
ClearPoint Neuro (CLPT) reported EBIT Margin of 69.9% for Q1 2026, up 273.0% on a YoY basis from 18.74% in Q1 2025, and down 3.29% sequentially from 67.68% in Q4 2025.
ClearPoint Neuro (CLPT) EBIT Margin (2011 - 2026) Analysis & Trends
ClearPoint Neuro (CLPT) has 15 years of EBIT Margin data on file, last reported at 69.9% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin rose 273.0% year-over-year to 69.9%; the trailing twelve-month figure through Mar 2026 stood at 65.2% (up 206.0% YoY), and the FY2025 full-year result was 65.36%, down 249.0% from the prior year.
- EBIT Margin declined to 69.9% in Q1 2026, from 67.68% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 55.19% in Q1 2024 to a low of 119.85% in Q2 2023.
- A 5-year average of 75.27% and a median of 72.53% in 2024 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin tumbled 3900 bps in 2023 and soared 5973 bps in 2024, its largest moves.
- Tracing CLPT's EBIT Margin over 5 years: stood at 86.37% in 2022, then rose by 20 bps to 69.1% in 2023, then decreased by 5 bps to 72.53% in 2024, then increased by 7 bps to 67.68% in 2025, then slipped by 3 bps to 69.9% in 2026.
- Business Quant data shows CLPT's EBIT Margin at 69.9% in Q1 2026, 67.68% in Q4 2025, and 59.54% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | ClearPoint Neuro | 434.51 Mn | 398.91 Mn | 7.76 Mn | -69.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.90% |
| Dec 31, 2025 | -67.68% |
| Sep 30, 2025 | -59.54% |
| Jun 30, 2025 | -61.64% |
| Mar 31, 2025 | -72.63% |
| Dec 31, 2024 | -72.53% |
| Sep 30, 2024 | -63.51% |
| Jun 30, 2024 | -60.12% |
| Mar 31, 2024 | -55.19% |
| Dec 31, 2023 | -69.10% |
| Sep 30, 2023 | -84.99% |
| Jun 30, 2023 | -119.85% |
| Mar 31, 2023 | -105.14% |
| Dec 31, 2022 | -86.37% |
| Sep 30, 2022 | -73.75% |
| Jun 30, 2022 | -80.85% |
| Mar 31, 2022 | -76.80% |
| Dec 31, 2021 | -92.99% |
| Sep 30, 2021 | -83.17% |
| Jun 30, 2021 | -99.82% |